A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study
Authors
Mead, A. J.Butt, N. M.
Nagi, W.
Whiteway, A.
Kirkpatrick, S.
Rinaldi, C.
Roughley, C.
Ackroyd, S.
Ewing, J.
Neelakantan, P.
Garg, M.
Tucker, D.
Murphy, J.
Patel, H.
Bains, R.
Chiu, G.
Hickey, J.
Harrison, C.
Somervaille, Tim C P
Issue Date
2022
Metadata
Show full item recordAbstract
Background: Myelofibrosis (MF) is a blood cancer associated with splenomegaly, blood count abnormalities, reduced life expectancy and high prevalence of disease-associated symptoms. Current treatment options for MF are diverse, with limited data on management strategies in real-world practice in the United Kingdom. Methods: The REALISM UK study was a multi-center, retrospective, non-interventional study, which documented the early management of patients with MF. The primary endpoint was the time from diagnosis to active treatment. Discussion: Two hundred patients were included (63% [n = 126/200] with primary MF; 37% [n = 74/200] with secondary MF). Symptoms and prognostic scores at diagnosis were poorly documented, with infrequent use of patient reported outcome measures. ‘Watch and wait’ was the first management strategy for 53.5% (n = 107/200) of patients, while the most commonly used active treatments were hydroxycarbamide and ruxolitinib. Only 5% of patients proceeded to allogeneic transplant. The median (IQR) time to first active treatment was 46 days (0–350); patients with higher risk disease were prescribed active treatment sooner. Conclusion: These results provide insight into real-world clinical practice for patients with MF in the United Kingdom. Despite the known high prevalence of disease-associated symptoms in MF, symptoms were poorly documented. Most patients were initially observed or received hydroxycarbamide, and ruxolitinib was used as first-line management strategy in only a minority of patients.Citation
Mead AJ, Butt NM, Nagi W, Whiteway A, Kirkpatrick S, Rinaldi C, et al. A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study. Vol. 13, Therapeutic Advances in Hematology. SAGE Publications; 2022.Journal
Ther Adv HematolDOI
10.1177/20406207221084487PubMed ID
35371428Additional Links
https://dx.doi.org/10.1177/20406207221084487Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1177/20406207221084487
Scopus Count
Collections
Related articles
- Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
- Authors: Gerds A, Su D, Martynova A, Pannell B, Mukherjee S, O'Neill C, Sekeres M, O'Connell C
- Issue date: 2018 Nov
- A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis.
- Authors: Ho PJ, Bajel A, Burbury K, Dunlop L, Durrant S, Forsyth C, Perkins AC, Ross DM
- Issue date: 2017 Mar
- Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial.
- Authors: Mead AJ, Milojkovic D, Knapper S, Garg M, Chacko J, Farquharson M, Yin J, Ali S, Clark RE, Andrews C, Dawson MK, Harrison C
- Issue date: 2015 Jul
- Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
- Authors: Harrison CN, Gupta VK, Gerds AT, Rampal R, Verstovsek S, Talpaz M, Kiladjian JJ, Mesa R, Kuykendall AT, Vannucchi AM, Palandri F, Grosicki S, Devos T, Jourdan E, Wondergem MJ, Al-Ali HK, Buxhofer-Ausch V, Alvarez-Larrán A, Patriarca A, Kremyanskaya M, Mead AJ, Akhani S, Sheikine Y, Colak G, Mascarenhas J
- Issue date: 2022 Sep
- Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib.
- Authors: Davis KL, Côté I, Kaye JA, Mendelson E, Gao H, Perez Ronco J
- Issue date: 2015